Table 1.
Association between Reg IV immunostaining and clinicopathological variables
| Reg IV | |||
|---|---|---|---|
| Positive | Negative | P‐value | |
| pT stage | |||
| ≤2b | 6 (22%) | 21 | 0.2001 |
| ≥2c | 8 (11%) | 63 | |
| Gleason score | |||
| ≤7 | 8 (11%) | 66 | 0.1001 |
| ≥8 | 6 (25%) | 18 | |
| Preoperative PSA concentration | |||
| <20 | 12 (13%) | 77 | 0.6122 |
| ≥20 | 2 (22%) | 7 | |
| MUC2 | |||
| Positive | 14 (19%) | 58 | 0.0182 |
| Negative | 0 (0%) | 26 | |
| Chromogranin A | |||
| Positive | 10 (32%) | 21 | 0.0012 |
| Negative | 4 (6%) | 63 | |
| EGFR | |||
| Positive | 8 (32%) | 17 | 0.0067 |
| Negative | 6 (8%) | 67 | |
| Phospho‐EGFR (Tyr1068) (n = 25) | |||
| Positive | 6 (67%) | 3 | 0.0099 |
| Negative | 2 (13%) | 14 | |
EGFR, epidermal growth factor receptor; PSA, prostate‐specific antigen.